B. Yan

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

Conivaptan, a Vasopressin-Receptor Antagonist, for the Treatment of Hyponatremia in Patients with and without Underlying Heart Failure

J. Ghali, B. Mcnutt, B. Yan, 2008 .

EFFICACY AND SAFETY OF CONIVAPTAN, A VASOPRESSIN V1A- AND V2-RECEPTOR ANTAGONIST, DURING PHASE 3 TRIALS OF PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA

J. Verbalis, S. Rosansky, L. Wagoner, 2007 .